The impact of cardiopulmonary manifestations on the mortality of SSC: A systematic review and meta-analysis of observational studies

Rheumatology (United Kingdom)

Volumn 51, Issue 6, 2012, Pages 1027-1036

  Komócsi, András ^a   Vorobcsuk, András ^a   Faludi, Réka ^a   Pintér, Tünde ^a   Lenkey, Zsófia ^a   Költo, Gyöngyvér ^b   Czirják, László ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Kaposi Mor County Hospital   (Hungary)

Author keywords

Cardiac manifestations; Clinical outcome; Mortality; Pulmonary hypertension; Systemic sclerosis

Indexed keywords

ARTICLE; CAUSE OF DEATH; HEART DISEASE; HUMAN; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; META ANALYSIS (TOPIC); MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCLERODERMA; SURVIVAL; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC SCLEROSIS;

CARDIOVASCULAR DISEASES; HUMANS; LUNG DISEASES; SCLERODERMA, SYSTEMIC;

EID: 84861478146     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker357     Document Type: Article

References (52)

1. Steen VD, Medsger TA Jr. Changes in causes of death in systemic sclerosis. Ann Rheum Dis 2007;47(Suppl. 5): 16-7.
2. Czirjak L, Pakozdi A, Kumanovics G et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008;67:59-63.
3. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118:2-10.
4. Arias-Nunez MC, Llorca J, Vazquez-Rodriguez TR et al. Systemic sclerosis in northwestern Spain: a 19-year epidemiologic study. Medicine 2008;87:272-80.
5. Allanore Y, Avouac J, Kahan A. Systemic sclerosis: an update in 2008. Joint Bone Spine 2008;75:650-5.
6. Valentini G, Black C. Systemic sclerosis. Best Pract Res Clin Rheumatol 2002;16:807-16.
7. Abu-Shakra M, Lee P. Mortality in systemic sclerosis: a comparison with the general population. J Rheumatol 1995;22:2100-2.
8. Bryan C, Howard Y, Brennan P et al. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 1996;35:1122-6.
9. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998;57:682-6.
10. Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998;37:750-5.
11. Ferri C, Valentini G, Cozzi F et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002;81: 139-53.
12. Scussel-Lonzetti L, Joyal F, Raynauld JP et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 2002; 81:154-67.
13. Simeon CP, Armadans L, Fonollosa V et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology 2003;42:71-5.
14. Alamanos Y, Tsifetaki N, Voulgari PV et al. Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002. Semin Arthritis Rheum 2005;34:714-20.
15. Hissaria P, Lester S, Hakendorf P et al. Survival in scleroderma: results from the population based south Australian register. Intern Med J 2010;41:381-90.
16. Joven BE, Almodovar R, Carmona L et al. Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital. Semin Arthritis Rheum 2010;39: 285-93.
17. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003;29:239-54.
18. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283: 2008-12.
19. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
20. Assassi S, Del JD, Sutter K et al. Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheum 2009;61:1403-11.
21. Abbott KC, Trespalacios FC, Welch PG et al. Scleroderma at end stage renal disease in the United States: patient characteristics and survival. J Nephrol 2002;15:236-40.
22. Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010;39:269-77.
23. Altman RD, Medsger TA Jr, Bloch DA et al. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991;34:403-13.
24. Komocsi A, Pinter T, Faludi R et al. Overlap of coronary disease and pulmonary arterial hypertension in systemic sclerosis. Ann Rheum Dis 2010;69:202-5.
25. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000;133: 600-3.
26. Steen VD, Costantino JP, Shapiro AP et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990;113:352-7.
27. DeMarco PJ, Weisman MH, Seibold JR et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002;46: 2983-9.
28. Hachulla E, Gressin V, Guillevin L et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800.
29. McGoon M, Gutterman D, Steen V et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(Suppl. 1):14S-34S.
30. Avouac J, Wipff J, Kahan A et al. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis 2008;67: 808-14.
31. Ryerson CJ, Nayar S, Swiston JR et al. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res 2010;11:12.
32. Galie N, Manes A, Negro L et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403.
33. Trad S, Amoura Z, Beigelman C et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006;54:184-91.
34. Mathai SC, Hummers LK, Champion HC et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009;60:569-77.
35. White B, Moore WC, Wigley FM et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-54.
36. Furst DE, Khanna D, Tseng CH et al. Patients with systemic sclerosis (SSc) enrolled in the scleroderma lung study (SLS) have a high mortality within 5 years of stopping cyclophosphamide (CYC). Clin Exp Rheumatol 2010;28(2 Suppl. 58):S94.
37. Allanore Y, Meune C, Vonk MC et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010;69:218-21.
38. Akram MR, Handler CE, Williams M et al. Angiographically proven coronary artery disease in scleroderma. Rheumatology 2006;45:1395-8.
39. Tarek E, Yasser AE, Gheita T. Coronary angiographic findings in asymptomatic systemic sclerosis. Clin Rheumatol 2006;25:487-90.
40. Allanore Y, Meune C, Kahan A. Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies. Curr Opin Rheumatol 2008;20: 697-702.
41. Tyndall AJ, Bannert B, Vonk M et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69: 1809-15.
42. Pinter T, Faludi R, Magyari B et al. Mechanism of coronary flow reserve reduction in systemic sclerosis: insight from intracoronary pressure wire studies. Rheumatology 2011; 50:781-8.
43. Hachulla E, Clerson P, Launay D et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 2007;34: 2423-30.
44. Allanore Y, Meune C, Vignaux O et al. Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and tissue-Doppler echography study. J Rheumatol 2006;33: 2464-9.
45. Duboc D, Kahan A, Maziere B et al. The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis. A positron emission tomographic study. Arthritis Rheum 1991;34:198-203.
46. Kahan A, Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheumatology 2006;45(Suppl. 4): iv14-7.
47. Kahan A, Devaux JY, Amor B et al. Nicardipine improves myocardial perfusion in systemic sclerosis. J Rheumatol 1988;15:1395-400.
48. Allanore Y, Meune C. Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin. Clin Exp Rheumatol 2010;28(5 Suppl. 62):S48-53.
49. Silman AJ. Scleroderma and survival. Ann Rheum Dis 1991;50:267-9.
50. Lee P, Langevitz P, Alderdice CA et al. Mortality in Systemic Sclerosis (Scleroderma). Quartely Journal of Medicine 1992;298:139-48.
51. Hachulla E, Carpentier P, Gressin. et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French Itiné rAIR-Sclé odermie study. Rheumatology 2009;48:304-8.
52. Kim J, Park SK, Moon KW et al. The prognostic factors of systemic sclerosis for survival among Koreans. Clin Rheumatol 2010;29:297-302.